3 years ago

Jellagen Nets £8.7M Series A to Advance Jellyfish-Based Regenerative Medicine

  • Welsh biotech startup Jellagen has raised £8.7 million in a Series A funding round to further develop its jellyfish-derived collagen technology for regenerative medicine

  • The company's Collagen Type 0, extracted from jellyfish, offers a potentially safer and more versatile alternative to traditional mammalian collagen

  • The funding will support Jellagen's research partnerships and the development of its technology platform.

    • ProblemHealthcare

      "Traditional collagen, commonly used in medicine for treating burns and wounds, comes from mammals and carries a higher risk of disease."

      Solution

      "Jellagen offers a purer and more versatile collagen derived from jellyfish, reducing the risk of disease associated with mammal-derived collagen."

      Covered on